Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19.
Evangelos AndreakosMaria PapadakiCharles N SerhanPublished in: Allergy (2021)
Coronavirus disease-19 (COVID-19) is a new disease caused by SARS-CoV-2. Since the beginning of 2020, it has become one of the main challenges of our times, causing a high incidence of severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure and death1 . At the root of COVID-19 lies the sudden development of 'cytokine storms', hyper-inflammatory responses involving the release of pro-inflammatory cytokines (e.g., TNF, IL-6, IL-1, IL-8, and MCP-1) that impair the gas exchange function of the lung and lead in select patients, mostly with underlying comorbidities, to multiorgan failure and death.
Keyphrases
- coronavirus disease
- sars cov
- acute respiratory distress syndrome
- respiratory syndrome coronavirus
- extracorporeal membrane oxygenation
- mechanical ventilation
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- oxidative stress
- rheumatoid arthritis
- low dose
- high dose
- prognostic factors
- peritoneal dialysis
- risk factors
- intensive care unit